Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment
Mohammad Farhad, Annah S. Rolig, William L. Redmond
OncoImmunology (2018) Vol. 7, Iss. 6
Open Access | Times Cited: 175

Showing 1-25 of 175 citing articles:

Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages
Natalia Ochocka, Paweł Segit, Kacper A. Walentynowicz, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 313
The Natural Cytotoxicity Receptors in Health and Disease
Alexander D. Barrow, Claudia Martín, Marco Colonna
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 290
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
Beatriz Ballester, Javier Milara, Julio Cortijo
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 3, pp. 593-593
Open Access | Times Cited: 261
Current Advancements in Pectin: Extraction, Properties and Multifunctional Applications
Vinay Chandel, Deblina Biswas, Swarup Roy, et al.
Foods (2022) Vol. 11, Iss. 17, pp. 2683-2683
Open Access | Times Cited: 220
Spatial genomics enables multi-modal study of clonal heterogeneity in tissues
Tongtong Zhao, Zachary Chiang, Julia W. Morriss, et al.
Nature (2021) Vol. 601, Iss. 7891, pp. 85-91
Open Access | Times Cited: 183
Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases
Akira Hara, Masayuki Niwa, Kei Noguchi, et al.
Biomolecules (2020) Vol. 10, Iss. 3, pp. 389-389
Open Access | Times Cited: 177
Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression
Ruiping Wang, Shumei Song, Jiang‐Jiang Qin, et al.
Cancer Cell (2023) Vol. 41, Iss. 8, pp. 1407-1426.e9
Open Access | Times Cited: 75
Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy
Mohamed J. Saadh, M. V. Mikhailova, Soheil Rasoolzadegan, et al.
European journal of medical research (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 47
Senescent endothelial cell-derived Galectin 3 promotes silicosis through endothelial-fibroblast and endothelial-macrophage crosstalk
Demin Cheng, Wenxiu Lian, Xinying Jia, et al.
Journal of Hazardous Materials (2025) Vol. 489, pp. 137605-137605
Closed Access | Times Cited: 2
Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived Galectin-3
Elmina Mammadova‐Bach, Jesús Gil‐Pulido, Edita Sarukhanyan, et al.
Blood (2020)
Open Access | Times Cited: 135
Reviewing the recent advances in application of pectin for technical and health promotion purposes: From laboratory to market
Masoumeh Moslemi
Carbohydrate Polymers (2020) Vol. 254, pp. 117324-117324
Closed Access | Times Cited: 133
Targeting phosphatidylserine for Cancer therapy: prospects and challenges
Wenguang Chang, Hongge Fa, Dandan Xiao, et al.
Theranostics (2020) Vol. 10, Iss. 20, pp. 9214-9229
Open Access | Times Cited: 92
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
Giorgio Frega, Qi Wu, Julie Le Naour, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 79
Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease
Vivek Narayan, Elizabeth Thompson, Biniyam G. Demissei, et al.
Journal of the American College of Cardiology (2020) Vol. 75, Iss. 21, pp. 2726-2737
Open Access | Times Cited: 77
Characterizing Macrophage Diversity in Metastasis-Bearing Lungs Reveals a Lipid-Associated Macrophage Subset
Danielle N. Huggins, Rebecca S. LaRue, Ying Wang, et al.
Cancer Research (2021) Vol. 81, Iss. 20, pp. 5284-5295
Open Access | Times Cited: 72
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
Brendan D. Curti, Yoshinobu Koguchi, Rom S. Leidner, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 4, pp. e002371-e002371
Open Access | Times Cited: 64
Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis
Shenglong Li, Yue Kang, Yu Zeng
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1879, Iss. 1, pp. 189033-189033
Closed Access | Times Cited: 41
Mitofusin 1 silencing decreases the senescent associated secretory phenotype, promotes immune cell recruitment and delays melanoma tumor growth after chemotherapy
Doménica Tarallo, Jennyfer Martínez, Alejandro Leyva, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 9
Deciphering functional tumor-immune crosstalk through highly multiplexed imaging and deep visual proteomics
Xiang Zheng, Andreas Mund, Matthias Mann
Molecular Cell (2025)
Open Access | Times Cited: 1
Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma
Mengjia Song, Qiuzhong Pan, Jieying Yang, et al.
British Journal of Cancer (2020) Vol. 123, Iss. 10, pp. 1521-1534
Open Access | Times Cited: 64
Tumor Microenvironment-Associated Extracellular Matrix Components Regulate NK Cell Function
Gustavo Rodrigues Rossi, Edvaldo da Silva Trindade, Fernando Souza‐Fonseca‐Guimaraes
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 56
Recent advances in conventional and unconventional vesicular secretion pathways in the tumor microenvironment
I.-Ying Kuo, Chih‐Hsiung Hsieh, Wan‐Ting Kuo, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 30
Novel immune checkpoint targets: A promising therapy for cancer treatments
Mohsina Patwekar, Nouroz Sehar, Faheem Patwekar, et al.
International Immunopharmacology (2023) Vol. 126, pp. 111186-111186
Closed Access | Times Cited: 22
Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies
Nikiforos-Ioannis Kapetanakis, Pierre Busson
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape
Giorgia Scafetta, Calogero D’Alessandria, Armando Bartolazzi
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top